Chemicals

Tesamorelin (usan)

We are Tesamorelin (usan) CAS:218949-48-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Tesamorelin (usan)

CAS.NO:218949-48-5

Synonyms:Tesamorelin (usan)

Tesamorelin

Physical and Chemical Properties:

Molecular Formula C220H364N72O67S

Molecular Weight 5121.74

Specification:

Appearance:White to off-white powder

Assay:≥98.0%

Packing:25 kg/drum, can also be packaged according to customer requirements

Storage:Store in a cool, ventilated place

Application:1. Tesamorelin is a new AIDS Drug Bodybuilders Take for Fat Loss

There are a wide variety of drugs that can help bodybuilders achieve major muscle gains and cut fat quickly and efficiently. But despite the large number of drugs already out there,new things that can help bodybuilders. And one of the latest potential bodybuilding drugs is EGRIFTA the brand name of the drug tesamorelin.

2. Tesamorelin, which is used to reduce belly fat in HIV patients, could be the ultimate key for bodybuilders who have trouble getting ripped abs.

3. Traditionally used to help HIV patients reduce body fat around their abdomens, EGRIFTA is now being tested for use in non-HIV patients. Even more interesting is the fact that some bodybuilders have already gotten a hold of the drug in hopes of vanishing body fat around their waist, and building the ultimate set of abs. To date, clinical studies suggest that Tesamorelin reduces visceral fat in HIV-infected patients with abdominal lipo-hypertrophy as well as reducing abdominal fat in all individuals studied.

4. Tesamorelin Boosts Cognition in Elderly

A peptide that improved several measures of cognitive function in cognitively normal and mildly impaired older individuals in a placebo-controlled trial, also reported greater subjective improvement in cognition relative to the placebo group.

Tesamorelin (usan)

Related News: Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).419563-22-7 “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.2,4-bis (fenilsulfonil) fenol CAS:177325-75-6 “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.34206-40-1 China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase.

Product Name
2,3,4-Trifluorobenzonitrile	View Details
2-Bromo-2′-fluoroacetophenone	View Details
4-Nitroisoindolin-1-one	View Details